
    
      The primary objective is to assess the efficacy of acute dosing of CVT-E002 in reducing the
      duration of URTI symptoms in children 3-11 years of age.

      The secondary objectives are to asses the efficacy of acute dosing of CVT-E002 in reducing:
      (1) symptom severity; (2) peak CARIFS scores and; (3) absenteeism for participant and/or
      parent/guardian. The ease of administration and the safety of acute dosing of CVT-E002 in
      children 3-11 years of age will also be assessed.
    
  